Gallicchio Margherita, Rosa Arianna Carolina, Benetti Elisa, Collino Massimo, Dianzani Chiara, Fantozzi Roberto
Department of Anatomy, Pharmacology and Forensic Medicine, University of Turin, Via Pietro Giuria, 9, 10125 Torino, Italy.
Br J Pharmacol. 2006 Mar;147(6):681-9. doi: 10.1038/sj.bjp.0706660.
Substance P (SP) is a neuropeptide involved in neurogenic inflammation and an agonist for NK(1), NK(2), and NK(3) receptors. SP induces prostaglandin (PG) production in various cell types, and these eicosanoids are responsible for numerous inflammatory and vascular effects. Cyclooxygenase (COX) are needed to convert arachidonic acid to PGs. The study evaluated the effect of SP on COX expression in human umbilical vein endothelial cells (HUVEC). COX-2 protein expression was upregulated by SP with a peak at 100 nM and at 20 h; in the same experimental conditions COX-1 protein expression was unchanged. A correlation between COX-2 expression and PGI(2) and PGE(2) release was detected. Dexamethasone (DEX) inhibited SP-mediated COX-2 expression. Mitogen-activated protein kinases (MAPK) p38 and p42/44 were activated by SP, whereas SB202190 and PD98059, inhibitors of these kinases, blocked COX-2 expression. 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl)phenyl-2(5H)-furanone (DFU), an experimental selective COX-2 inhibitor, blocked SP-induced PG release. By RT-PCR and Western blot analysis, we demonstrated that NK(1) and NK(2) but not NK(3) receptors are present on HUVEC. Selective NK(1) and NK(2) agonists, namely [Sar(9), Met(O(2))(11)]SP and [beta-Ala(8)] NKA(4-10), upregulated COX-2 protein expression and PG production, whereas senktide (Suc-Asp-Phe-MePhe-Gly-Leu-Met-NH(2)), a selective NK(3) agonist, was ineffective in this respect. The NK(1) selective antagonist L703,606 ((cis)-2-(diphenylmethyl)-N-((2-iodophenyl)-methyl)-1-azabicyclo(2.2.2)octan-3-amine) and the NK(2) selective antagonist SR 48,968 ((S)-N-methyl-N-(4-(4-acetylamino-4-phenylpiperidino)-2-(3,4 dichlorophenyl)butyl) benzamide) competitively antagonised SP-induced effects. The study shows HUVEC to possess functional NK(1) and NK(2) receptors, which mediate the ability of SP to induce expression of COX-2 in HUVEC, thus showing a previously-undetected effect of SP on endothelial cells.
P物质(SP)是一种参与神经源性炎症的神经肽,是NK(1)、NK(2)和NK(3)受体的激动剂。SP可诱导多种细胞类型产生前列腺素(PG),这些类花生酸负责多种炎症和血管效应。环氧化酶(COX)是将花生四烯酸转化为PG所必需的。该研究评估了SP对人脐静脉内皮细胞(HUVEC)中COX表达的影响。SP上调了COX-2蛋白表达,在100 nM时达到峰值,时间为20小时;在相同实验条件下,COX-1蛋白表达未发生变化。检测到COX-2表达与前列环素(PGI(2))和前列腺素E2(PGE(2))释放之间存在相关性。地塞米松(DEX)抑制SP介导的COX-2表达。丝裂原活化蛋白激酶(MAPK)p38和p42/44被SP激活,而这些激酶的抑制剂SB202190和PD98059可阻断COX-2表达。5,5-二甲基-3-(3-氟苯基)-4-(4-甲磺酰基)phenyl-2(5H)-呋喃酮(DFU),一种实验性选择性COX-2抑制剂,可阻断SP诱导的PG释放。通过逆转录聚合酶链反应(RT-PCR)和蛋白质印迹分析,我们证明HUVEC上存在NK(1)和NK(2)受体,但不存在NK(3)受体。选择性NK(1)和NK(2)激动剂,即[Sar(9), Met(O(2))(11)]SP和[β-Ala(8)]神经激肽A(NKA(4-10)),上调了COX-2蛋白表达和PG产生,而选择性NK(3)激动剂senktide(Suc-Asp-Phe-MePhe-Gly-Leu-Met-NH(2))在这方面无效。NK(1)选择性拮抗剂L703,606((顺式)-2-(二苯甲基)-N-((2-碘苯基)-甲基)-1-氮杂双环(2.2.2)辛烷-3-胺)和NK(2)选择性拮抗剂SR 48,968((S)-N-甲基-N-(4-(4-乙酰氨基-4-苯基哌啶基)-2-(3,4-二氯苯基)丁基)苯甲酰胺)竞争性拮抗SP诱导的效应。该研究表明HUVEC具有功能性NK(1)和NK(2)受体,它们介导了SP诱导HUVEC中COX-2表达的能力,从而显示出SP对内皮细胞的一种先前未被发现的效应。